Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diurnal Nears Market With Novel Adrenal Insufficiency Products

This article was originally published in Scrip

Executive Summary

Two potential orphan drugs developed by the UK's newly public endocrinology speciality company, Diurnal Group, are in Phase III clinical trials, and the first of these, Infacort (immediate-release hydrocortisone) for pediatric patients with insufficient levels of the chemically-related essential hormone cortisol, could be approved in its first markets within 18 months, by the end of 2017.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel